Parallax Volatility Advisers’s Epizyme, Inc EPZM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-44,591
Closed -$371K 3620
2021
Q2
$371K Buy
44,591
+4,052
+10% +$34.2K ﹤0.01% 2288
2021
Q1
$353K Buy
40,539
+8,211
+25% +$85K ﹤0.01% 2487
2020
Q4
$351K Buy
+32,328
New +$399K ﹤0.01% 2605
2019
Q1
Sell
-10,100
Closed -$62K 4354
2018
Q4
$62K Buy
+10,100
New +$77.1K ﹤0.01% 2060
2018
Q1
Sell
-7,476
Closed -$94K 4755
2017
Q4
$94K Buy
+7,476
New +$109K ﹤0.01% 2843

Other funds holding EPZM

Parallax Volatility Advisers's EPZM Position: Q3 2021 in Review

Parallax Volatility Advisers sold out of Epizyme, Inc (EPZM) in Q3 2021, closing a stake of 44,591 shares — an estimated $371K sold.

Parallax Volatility Advisers first reported a position in EPZM in Q4 2017 and held it in 5 quarters. The position peaked at $371K in Q2 2021. 116 funds tracked by Wall St. Rank hold EPZM as of Q3 2021.

  • Parallax Volatility Advisers reported no remaining Epizyme, Inc position as of Q3 2021 after selling out during the quarter.
  • Parallax Volatility Advisers sold 44,591 Epizyme, Inc shares in Q3 2021, an estimated $371K.
  • Parallax Volatility Advisers first reported a position in Epizyme, Inc in Q4 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Epizyme, Inc position peaked at $371K in Q2 2021.
  • 116 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2021.

Based on Parallax Volatility Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.